Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113905 · ClinicalTrials.gov registry record
Role of Beta-Endorphin in Cancer Therapy Fatigue
A clinical trial, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- 18
- Enrollment target
NCT01113905: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT01113905 is a clinical trial that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01113905 was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- 18 participants
- Enrollment target
Study Summary
The investigators aim to test whether beta-endorphin, a substance our bodies make in response to painful and stressful stimuli, plays a causative role in radiation-induced fatigue that cancer patients receiving radiation therapy commonly experience. If this is so, the investigators' hope is to direct efforts at treating radiation-induced fatigue using agents that block the action of beta-endorphin with the aim of improving quality of life for patients undergoing radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-08 |
Why NCT01113905 stopped before completion
NCT01113905 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01113905 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01113905 about?
NCT01113905 is a clinical study titled "Role of Beta-Endorphin in Cancer Therapy Fatigue". The investigators aim to test whether beta-endorphin, a substance our bodies make in response to painful and stressful stimuli, plays a causative role in radiation-induced fatigue that cancer patients receiving radiation therapy commonly experience. If this is so, the investigators' hope is to direc...
What is the current status of trial NCT01113905?
This trial is currently terminated. The enrollment target is 18 participants. The study started on 2009-12. Estimated completion is 2014-08.
Who is sponsoring clinical trial NCT01113905?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia